Intellia Therapeutics, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm for More Information - NTLA

Core Viewpoint - Intellia Therapeutics, Inc. is facing a class action lawsuit due to allegations of misleading investors regarding the progress and viability of its NTLA-3001 program for treating alpha-1 antitrypsin deficiency-associated lung disease, which has now been discontinued [1][2]. Summary by Relevant Sections Allegations - The lawsuit claims that Intellia's management provided investors with optimistic timelines for the NTLA-3001 study, specifically stating that the first patient would be dosed in the second half of 2024 [1]. - It is alleged that the company failed to disclose a significant decline in demand for viral-based editing technologies, as non-viral methods gained favor for their cost-effectiveness and efficiency [1]. - The truth about the company's situation was revealed on January 9, 2025, when Intellia announced a reorganization, halting all NTLA-3001 research and reducing its workforce by 27% [1]. Stock Price Impact - Following the announcement of the discontinuation of NTLA-3001, Intellia's stock price dropped from $12.02 per share on January 8, 2025, to$10.20 per share on January 10, 2025 [1]. Next Steps for Shareholders - Shareholders who purchased NTLA shares during the specified class period are encouraged to register for the class action by April 14, 2025, to potentially become lead plaintiffs [2]. - Registered shareholders will receive updates through a portfolio monitoring software regarding the case's progress [2]. Law Firm's Commitment - The Gross Law Firm aims to protect investors' rights and seeks recovery for those who suffered losses due to misleading statements or omissions by companies [3].